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Introduction 
While medicines usually promote health, they can also be expensive and cause harm. It is, 
therefore, important that needed medicines are developed, and that they are safe, effective 
and affordable. Unfortunately, progress towards this goal is inconsistent. We argue that forces 
other than commercialisation need to be considered, and that there is a need to advocate for a 
drug development process that fills important gaps, reduces clinical uncertainty and promotes 
the rational use of medicines. 
The trouble with drug development 
To maximize clinical benefit and minimize harm to patients, clinicians are increasingly aspiring 
to an ‘evidence-based’ or ‘rational’ approach to prescribing (1). The relevance and quality of the 
evidence available about pharmacotherapies is, therefore, essential to good clinical care. 
Ideally, drug discovery and clinical research (‘drug development’) should serve to advance 
medical knowledge and improve the prevention and management of disease. In reality, 
however, it is increasingly apparent that drug development is failing in fundamental ways and 
that there are major gaps in the evidence available to clinicians stemming from (for example) 
(2):  
 measuring new agents against placebo rather than “gold standard” therapy (where this 
is not appropriate) or assessing non-inferiority rather than superiority (particularly in 
phase III/IV studies);  
 not asking questions about substantive outcomes such as survival or cost-effectiveness;  
 using surrogate outcome indicators which do not always reflect clinical outcomes and 
have not always been validated sufficiently; 
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 testing new drugs in populations which differ, for example genetically, from those who 
will be receiving the intervention; 
 continuing to rely on randomised controlled trials and meta-analyses to study responses  
that do not necessarily reflect real-world clinical practice nor the complexity of diseases 
that are biologically heterogeneous. 
   
This has two major effects. On the one hand there are some areas of practice in which there 
has been relatively limited progress (e.g. pharmacotherapy for pancreatic cancer, Alzheimer’s 
disease and malaria). There are also areas in which progress has been made but where research 
has produced uncertainty as to what constitutes optimal treatment. In the case of breast 
cancer, for example, there are now a large number of effective agents including hormonal 
response modulators, cytotoxics, monoclonal antibodies and angiogenesis inhibitors.  While 
this has improved outcomes for women with breast cancer, it has also created uncertainty 
regarding the use of early data and surrogate endpoints in drug approval and clinical practice; 
optimal combinations and sequencing of therapy; the duration of therapy; the use of 
maintenance therapy and the relevance to the choice of therapy of prior adjuvant therapy and 
individual patient characteristics (2). Similar problems can be found in many clinical areas 
including the treatment of rheumatoid arthritis, multiple myeloma, schizophrenia and viral 
hepatitis. 
It is essential, therefore, that we not only conduct more pharmaceutical research, but also take 
a more critical approach to the research that is done. This, in turn, requires an understanding of 
the range of factors (other than medical utility) that might influence the focus, direction, quality 
and integrity of drug discovery and clinical research.  
What research is done, and why? 
Medical research has two broad epistemic and moral goals: to advance biomedical knowledge 
and improve human health. In recent years, however, it has become increasingly clear that the 
research agenda is shaped by a range of influences, including: 
 The source of funding for research, 
 The institutional context in which research is done, 
 Advances in understanding of health, diseases, diagnostics and therapeutics, 
 The regulatory environment, 
 Information technologies, 
 Changing consumer expectations,  
 The forces of globalization and 
 The increasing influence of ‘payers’ or ‘purchasers’. 
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This, in turn, has major ethical, scientific, medical and public health implications.  
For the most part, debate surrounding influences on drug discovery and clinical research has 
concerned itself with the impact of commerce, particularly the pharmaceutical industry, on the 
goals and conduct of research. While major distortions of research are now rare, practices of 
ongoing concern include the development of drugs which are very similar to existing products 
and the manipulation of drug doses, study populations, or the lengths of studies in order to 
more likely obtain the outcome of (commercial) interest (2). All of these practices are, in turn, 
shaped by a rapidly changing commercial and regulatory environment in which “blockbuster” 
drugs are going off-patent, pipelines are relatively empty and regulators are demanding ever 
more information (3). 
  
It is increasingly difficult, however, to draw practical and moral distinctions between 
commercial and academic research. Many research institutes, universities and academic 
medical centres now position themselves as ‘partners’ with private industry and share control 
over the design, conduct or dissemination of research (4), and increasingly government funding 
bodies and research institutions demand that researchers consider the commercial possibilities 
of their research and the concordance of their research with commercial and political interests 
(5). Many of the criticisms of commercially-funded research therefore apply increasingly to 
government funded academic research being conducted in public institutions such as 
universities and health services.  
 
Clinical research is also no longer practiced primarily in Europe, North America and Japan, with 
increasing numbers of clinical trials being conducted in Asian countries (e.g. China and India), 
South America (especially Brazil), Latin America and the countries of Eastern Europe and the 
Russian Federation (6). While this geographical shift in international research activity (driven 
largely by pharmaceutical companies) is welcomed by developing world governments and 
supported by major international research organizations such as the National Institutes of 
Health, and while the quality of this research, undertaken in support of registration in U.S., 
European and Japanese markets, is usually good, it can be difficult to be clear about the validity 
and generalizability of research results which are derived from populations with different 
genomic profiles (e.g. polymorphisms in particular enzymes), diets, comorbidities, life 
expectancies, and so on (7, 8). 
The research that is being done is also being influenced by new scientific paradigms—which 
influence both the questions asked, and the methods used, in clinical research. The established 
hierarchies of research evidence, which privilege systematic reviews and meta-analyses of 
randomized controlled trials (RCTs) are, for example, challenged by scientific insights which 
have established that diseases and responses to therapies are much more heterogeneous (e.g. 
genetically) than previously thought. (9). In this context, RCTs are difficult and expensive to 
conduct (especially where more than one aberrant pathway or target has been identified and 
where combinations of targeted agents may be necessary) and meta-analyses have little 
meaning. Indeed, it may be the case that the focus will need to shift away from randomised, 
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controlled trials and towards other clinical research designs as well as basic research since there 
will simply be too many drug combinations to test empirically in trials.  
The other major change in research over the past few decades is that it is no longer practiced in 
the rarefied climes of laboratories but rather in the full glare of public attention. Consumer 
groups, for example those concerned with HIV-AIDS and multiple myeloma, are increasingly 
interested in ensuring that pharmaceutical research generates the products and clinical 
outcomes that matter to them (10). Likewise, the agencies that fund clinical research, or 
approve and fund the products of this research, unquestionably influence the research agenda 
through demands for evidence of comparative effectiveness, cost-effectiveness and long-term 
safety. 
Avoiding commercial myopia 
It is perhaps understandable that attention has focused on the way that industry interests 
might bias the type of drug discovery and clinical research being done. But it is now increasingly 
clear that commercial interests are not the only influence on drug development. This means 
that researchers, clinicians and policymakers need to address the full range of influences on 
drug development and clinical research, the impact these have upon the quality and relevance 
of research activity and the ways in which these may impede or facilitate rational prescribing 
and evidence-based practice.  
Getting the drugs we need 
This reflection might, in turn, highlight a range of different strategies for getting the drugs we 
need (some of which are already being explored), such as: 
1. Generating more epidemiological information (and increasing the impact of existing 
information) about the unmet needs of target communities, and better aligning drug 
development with the burden of disease; 
2. Improving government funding of drug development so that, in addition to facilitating 
commercial drug development, it is in the public interest and meets the needs of populations 
under-served by industry; 
3. Developing new mechanisms to encourage industry to invest in areas of unmet need; 
4. Increasing collaboration between academia and industry, as well as between different 
companies, to streamline drug development processes and avoid repeating costly mistakes; 
5. Encouraging the epidemiology, biostatistics and information technology communities to 
rethink hierarchies of evidence and research designs, and to develop information systems that 
support every stage of the drug development process, including post-approval cost-
effectiveness evaluations and  pharmacogenomic and biomarker research; 
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6. Encouraging national and global harmonisation and integration of research, regulatory and 
reimbursement processes so that these processes can be made more efficient and so that 
“value” (benefit-risk) considerations can be given as much weight as considerations of efficacy 
and safety; 
7. Rethinking the roles that consumers, advocacy groups and purchasers can play at each stage 
of the drug development process. 
More generally, we need not (only) more drugs discovered and more clinical research, but also 
to systematically explore new models of drug development, into which are built the necessary 
incentives and disincentives to ensure that industry, academia and government all work 
together towards producing the drugs we need.   
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